Myelofibrosis Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Lynk Pharma, Samus Therapeutics, Taiga

The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Myelofibrosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.

Some of the key takeaways from the Myelofibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Myelofibrosis treatment therapies with a considerable amount of success over the years. 
• Myelofibrosis companies working in the treatment market are Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others, are developing therapies for the Myelofibrosis treatment 

• Emerging Myelofibrosis therapies in the different phases of clinical trials are- LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others are expected to have a significant impact on the Myelofibrosis market in the coming years.   
• In June 2022, Cellenkos reported that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to launch a Phase Ib, open-label study of CK0804 in myelofibrosis patients who respond poorly to ruxolitinib
• In June 2022, The patented oral PIM kinase inhibitor TP-3654 developed by Sumitomo Pharma Oncology for the treatment of myelofibrosis was given Orphan Drug Designation by the US FDA.
• In June 2022, Updated favorable results from Imago Biosciences’ ongoing worldwide Phase II clinical study assessing bomedemstat in patients with advanced myelofibrosis were presented. In general, bomedemstat was well-tolerated and safe by myelofibrosis patients. In 36% of patients, dysgeusia (altered taste), the most prevalent non-hematologic adverse event (AE) associated with bomedemstat, resulted in discontinuation in 1 patient. According to the Investigator, there were 14 serious adverse events (SAEs) that were linked to bomedemstat.
• In June 2022, New findings from Cohort 3 of AbbVie’s Phase II REFINE study of experimental navitoclax combined with ruxolitinib in patients with myelofibrosis (MF), a rare and challenging to treat blood malignancy, were released. These findings confirmed the value of early myelofibrosis management and the possibility of better clinical outcomes.
• In May 2022, Tasquinimod was given Orphan Drug Designation by the US FDA for the treatment of myelofibrosis, according to a statement from Active Biotech.
• In February 2022, With regard to patents covering the use of tasquinimod and other S100 inhibitors for the treatment of myelofibrosis, Active Biotech entered into an exclusive license arrangement with Oncode Institute in the Netherlands.
• In April 2022, The biopharmaceutical business Sierra Oncology, which specializes in therapies for uncommon kinds of cancer, will be acquired by GlaxoSmithKline for an agreed-upon $1.9 billion. This information follows Sierra Oncology’s early-year positive top-line results from the MOMENTUM phase III trial. This medication is a valuable addition to GSK’s current hematology portfolio.

Myelofibrosis Overview

A rare condition called myelofibrosis causes the normal bone marrow tissue to eventually be replaced by a fibrous, scar-like substance.It is categorized as a particular form of chronic leukaemia and is a member of the myeloproliferative diseases family of blood diseases.This causes gradual bone marrow loss over time.

Get a Free Sample PDF Report to know more about Myelofibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight

Emerging Myelofibrosis Drugs Under Different Phases of Clinical Development Include:

• LNK01002: Lynk Pharmaceuticals
• PU-H-71: Samus Therapeutics
• TBX-2400: Taiga Biotechnologies          
• BMS-986158: Bristol-Myers Squibb
• TP-3654: Sumitomo Pharma Oncology, Inc.
• KER-050: Keros Therapeutics, Inc.
• GB2064: Galecto Biotech AB
• 9-ING-41: Actuate Therapeutics Inc.
• Selinexor: Karyopharm Therapeutics In
• Navitoclax: AbbVie
• Momelotinib: Sierra Oncology
• Parsaclisib: Incyte Corporation

Myelofibrosis Route of Administration

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Myelofibrosis Molecule Type

Myelofibrosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type 

Myelofibrosis Pipeline Therapeutics Assessment

• Myelofibrosis Assessment by Product Type
• Myelofibrosis By Stage and Product Type
• Myelofibrosis Assessment by Route of Administration
• Myelofibrosis By Stage and Route of Administration
• Myelofibrosis Assessment by Molecule Type
• Myelofibrosis by Stage and Molecule Type

DelveInsight’s Myelofibrosis Report covers around 45+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myelofibrosis product details are provided in the report. Download the Myelofibrosis pipeline report to learn more about the emerging Myelofibrosis therapies

Some of the key companies in the Myelofibrosis Therapeutics Market include:

Key companies developing therapies for Myelofibrosis are – Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., and others.

Myelofibrosis Pipeline Analysis:

The Myelofibrosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
• Myelofibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myelofibrosis drugs and therapies

Myelofibrosis Pipeline Market Drivers

• Increase in R&D for the development of new and effective drug for the treatment • Increasing Incidence in Elderly Population, development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.

Myelofibrosis Pipeline Market Barriers

• However, side effects associated with the drugs, high cost of therapy and other factors are creating obstacles in the Myelofibrosis Market growth.

Scope of Myelofibrosis Pipeline Drug Insight    

• Coverage: Global
• Key Myelofibrosis Companies: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others
• Key Myelofibrosis Therapies: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others
• Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies
• Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers 

Request for Sample PDF Report for Myelofibrosis Pipeline Assessment and clinical trials

Table of Contents 

1. Myelofibrosis Report Introduction

2. Myelofibrosis Executive Summary

3. Myelofibrosis Overview

4. Myelofibrosis- Analytical Perspective In-depth Commercial Assessment

5. Myelofibrosis Pipeline Therapeutics

6. Myelofibrosis Late Stage Products (Phase II/III)

7. Myelofibrosis Mid Stage Products (Phase II)

8. Myelofibrosis Early Stage Products (Phase I)

9. Myelofibrosis Preclinical Stage Products

10. Myelofibrosis Therapeutics Assessment

11. Myelofibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myelofibrosis Key Companies

14. Myelofibrosis Key Products

15. Myelofibrosis Unmet Needs

16 . Myelofibrosis Market Drivers and Barriers

17. Myelofibrosis Future Perspectives and Conclusion

18. Myelofibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services